Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from GlaxoSmithKline ( (GB:GSK) ).
GSK has secured Orphan Drug Designation in Japan for risvutatug rezetecan, a B7-H3-targeted antibody-drug conjugate, for the treatment of small-cell lung cancer. The designation, based on early phase I data showing durable responses in extensive-stage disease, marks the sixth major regulatory recognition for this asset as GSK advances it across multiple solid tumour indications.
Small-cell lung cancer accounts for a significant share of lung cancer cases in Japan and extensive-stage disease carries high relapse rates and poor survival, underscoring the need for new options. With a global phase III trial in relapsed extensive-stage SCLC already under way and multiple U.S. and European designations in hand, the Japanese status strengthens GSK’s late‑stage oncology pipeline and could enhance its competitive position in hard‑to‑treat solid tumours.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £2136.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company focused on developing and commercialising medicines and vaccines across a range of therapeutic areas. The group aims to combine science, technology and talent to address major diseases worldwide, with an increasing emphasis on oncology and other high‑need conditions.
Average Trading Volume: 8,894,945
Technical Sentiment Signal: Buy
Current Market Cap: £78.03B
Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.